CLOV vs OCGN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 17, 2026

CLOV

39.0
AI Score
VS
OCGN Wins

OCGN

45.0
AI Score

Investment Advisor Scores

CLOV

39score
Recommendation
SELL

OCGN

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV OCGN Winner
Revenue 1.49B 3.02M CLOV
Net Income 55.34M -44.05M CLOV
Net Margin 3.7% -1457.8% CLOV
Operating Income 55.34M -34.28M CLOV
ROE 14.7% 266.1% OCGN
ROA 7.7% -35.5% CLOV
Total Assets 720.33M 124.21M CLOV
Current Ratio 1.50 0.80 CLOV
Free Cash Flow 131.55M -34.02M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +6.8% · 3M: -7.7% OCGN 1M: -27.4% · 3M: -15.4%

Current Technical Phase

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.1 · Price: $4.56

OCGN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.7%), weak momentum, RSI 29

RSI (14): 29.3 · Price: $1.00

Fundamentals Snapshot

Metric CLOV OCGN
Market Cap
Forward P/E 28.8 -3.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.6% 0.1%
Gross Margin 0.2% -8.6%
Operating Margin 0.0% -11.1%
EPS -0.05 -0.24
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, OCGN is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.